Paris saponin II inhibits human ovarian cancer cell-induced angiogenesis by modulating NF-κB signaling

Oncology Reports
Mei YangXue Xiao

Abstract

The clinical applications of Rhizoma paridis in traditional Chinese medicine are well known. However, the therapeutic potential of Rhizoma paridis and its active component such as Paris saponin I (polyphyllin D) and Paris saponin II (PSII) (formosanin C) in cancer treatments have not yet been fully explored. Recent studies have demonstrated that PSII and chemoagents exhibit comparable inhibitory affects against human ovarian cancer cell growth. Since NF-κB, a ubiquitous transcription factor that plays an important role in cancer biology, is often associated with gynecological cancers, in the present study, we evaluated the possibility that PSII modulates NF-κB activity and VEGF-mediated angiogenesis and elucidated the molecular mechanisms underlying such effects. We assessed the effects of PSII on NF-κB activity in SKOV3 tumor cells and on tumor cell induced-angiogenesis using standardized angiogenesis in vitro, ex vivo and in vivo assays, western blot analysis and kinase assay. We also assessed the effect of the super-engineered repressor of IĸBα and its effect, in combination with PSII treatment on tumor growth and angiogenesis in xenograft athymic mouse models of ovarian cancer (SKOV3 and SKOV3/mutant IĸBα cells) using color...Continue Reading

References

Nov 21, 1995·Proceedings of the National Academy of Sciences of the United States of America·D C SchererD W Ballard
Jan 17, 2003·Cell Research·Weiming XuIan G Charles
Apr 8, 2003·Current Medicinal Chemistry. Anti-cancer Agents·John W HoChun Pong Chan
Mar 16, 2004·Cancer Treatment and Research·Sybill Patan
Jun 29, 2004·Proceedings of the National Academy of Sciences of the United States of America·Debajit K BiswasJ Dirk Iglehart
Sep 24, 2004·Cancer Cell·Bharat B Aggarwal
Oct 1, 2004·The British Journal of Radiology·D Cosgrove
Dec 16, 2005·Nature·Peter Carmeliet
Dec 16, 2005·Nature·Napoleone Ferrara, Robert S Kerbel
May 9, 2008·The New England Journal of Medicine·Robert S Kerbel
Feb 23, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Gong YangJinsong Liu
Jul 19, 2011·Cancer Treatment Reviews·Jordan Schmitt, Daniela Matei
Oct 5, 2011·Journal of Experimental & Clinical Cancer Research : CR·Niels Eckstein
Jan 22, 2013·CA: a Cancer Journal for Clinicians·Rebecca SiegelAhmedin Jemal

❮ Previous
Next ❯

Citations

Oct 5, 2017·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Ling-Yan JiaYi Charlie Chen
Nov 18, 2017·Environmental Toxicology·Shuli ManWenyuan Gao
Nov 9, 2021·Frontiers in Oncology·Ruyi LiZhe-Sheng Chen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.